国家安全性：British/American｜年数，年数：1964
Ascientist by training，John D.Young has over35years of experience in the healthcare industry and will bring a wealth of experience in leadership，strategy，business development and commercialization of innovative medicines to the Novartis Board of Directors。He joined Pfizer in 1987as a sales representative and held positions of increasing seniority across the company，including as a member of Pfizer’s executive leadership team from2012。As Pfizer’s group president and chief business officer from2019until2022，John also played an integral role in the development and delivery of the Pfizer-BioNTech COVID-19vaccine。
专业化，专业化
- Senior advisor to the CEO，Pfizer，US（January‑June 2022）
- Group president and chief business officer，Pfizer，US（2019‑2022）
- Group president，innovative health business，Pfizer，US（2018）
- Group president，essential health business，Pfizer，US（2014‑2017）
- President and general manager，global primary care business unit，Pfizer，US（2012‑2013）
- Regional president，primary care business unit for Europe and Canada，Pfizer，UK（2009‑2012）
- Various managerial positions，Pfizer，UK and Australia（1987‑2008）
手动，手动
- Board member，Johnson Controls International，Ireland
- Board member，Arvinas Inc，US
- Board member，Imbria Pharmaceuticals，US
- Board member，Haleon，UK（2022-February 2023）
- Board member，GSK Consumer Health Joint Venture，UK（2019-2022）
- Board member，Biotechnology Innovation Organization（BIO），US（2018-2021）
- US bio-pharmaceutical representative，UK Government Life Sciences Council，UK（2007‑2021）
- Board member，National Committee for US China Relations，US（2014-2017）
- Board member，European Federation of Pharmaceutical Industries and Associations（EFPIA），Belgium（2012-2017）
产量，产量
- 主业务导纳，通用性的Strathclyde，UK
- Bachelor’s degree in biological sciences，University of Glasgow，UK
关键skills
- 介质/healthcare/R&D
- Leadership/management
- Finance/accounting
- Law/regulatory/risk management
